Akt activation synergizes with Trp53 loss in oral epithelium to produce a novel mouse model for head and neck squamous cell carcinoma

Cancer Research

Volumn 69, Issue 3, 2009, Pages 1099-1108

  Moral, Marta ^a   Segrelles, Carmen ^a,d   Lara, M Fernanda ^a,f   Martínez Cruz, Ana Belén ^a   Lorz, Corina ^a   Santos, Mirentxu ^a   García Escudero, Ramón ^a   Lu, Jerry ^d   Kiguchi, Kaoru ^d   Buitrago, Agueda ^a   Costa, Clotilde ^a   Saiz, Cristina ^a   Rodriguez Peralto, Jose L ^b   Martinez Tello, Francisco J ^b   Rodriguez Pinilla, Maria ^c   Sanchez Cespedes, Montserrat ^c   Garín, Marina ^a   Grande, Teresa ^a   Bravo, Ana ^e   DiGiovanni, John ^d   Paramio, Jesús M ^a   more..

^a CIEMAT   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^c Centro Nacional de Investigaciones Oncológicas   (Spain)

^d UNIVERSITY OF TEXAS   (United States)

^e UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^f STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN KINASE B; PROTEIN P53; STAT3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVITY; HEAD AND NECK CARCINOMA; LYMPH NODE METASTASIS; MOUSE; MOUTH MUCOSA; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SENESCENCE; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CELL TRANSFORMATION, NEOPLASTIC; DISEASE MODELS, ANIMAL; ENZYME ACTIVATION; HEAD AND NECK NEOPLASMS; HUMANS; MICE; MICE, INBRED C57BL; MICE, INBRED DBA; MICE, TRANSGENIC; MOUTH MUCOSA; PROTO-ONCOGENE PROTEINS C-AKT; TUMOR SUPPRESSOR PROTEIN P53;

EID: 59149092491     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-3240     Document Type: Article

References (43)

1. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354:567-78.
2. Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003;349:2091-8.
3. Bourhis J, Overgaard J, Audry H, et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet 2006;368:843-54.
4. Baselga J, Trigo JM, Bourhis J, et al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2005;23:5568-77.
5. Neville BW, Day TA. Oral cancer and precancerous lesions. CA Cancer J Clin 2002;52:195-215.
6. Lu SL, Herrington H, Wang XJ. Mouse models for human head and neck squamous cell carcinomas. Head Neck 2006;28:945-54.
7. Mao L, Hong WK, Papadimitrakopoulou VA. Focus on head and neck cancer. Cancer Cell 2004;5:311-6.
8. Harper LJ, Piper K, Common J, Fortune F, Mackenzie IC. Stem cell patterns in cell lines derived from head and neck squamous cell carcinoma. J Oral Pathol Med 2007;36:594-603.
9. Prince ME, Sivanandan R, Kaczorowski A, et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci U S A 2007;104:973-8.
10. Perez-Ordonez B, Beauchemin M, Jordan RC. Molecular biology of squamous cell carcinoma of the head and neck. J Clin Pathol 2006;59:445-53.
11. Jimeno A, Kulesza P, Wheelhouse J, et al. Dual EGFR and mTOR targeting in squamous cell carcinoma models, and development of early markers of efficacy. Br J Cancer 2007;96:952-9.
12. Segrelles C, Lu J, Hammann B, et al. Deregulated activity of Akt in epithelial basal cells induces spontaneous tumors and heightened sensitivity to skin carcinogenesis. Cancer Res 2007;67:10879-88.
13. Segrelles C, Moral M, Lorz C, et al. Constitutively active Akt induces ectodermal defects and impaired bone morphogenetic protein signaling. Mol Biol Cell 2008;19:137-49.
14. Jonkers J, Meuwissen R, van der Gulden H, Peterse H, van der Valk M, Berns A. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat Genet 2001;29:418-25.
15. Martinez-Cruz AB, Santos M, Lara MF, et al. Spontaneous squamous cell carcinoma induced by the somatic inactivation of retinoblastoma and Trp53 tumor suppressors. Cancer Res 2008;68:683-92.
16. Lara MF, Garcia-Escudero R, Ruiz S, et al. Gene profiling approaches help to define the specific functions of retinoblastoma family in epidermis. Mol Carcinog 2008;47:209-21.
17. Lara MF, Santos M, Ruiz S, et al. p107 acts as a tumor suppressor in pRb-deficient epidermis. Mol Carcinog 2008;47:105-13.
18. Ruiz S, Santos M, Segrelles C, et al. Unique and overlapping functions of pRb and p107 in the control of proliferation and differentiation in epidermis. Development 2004;131:2737-48.
19. Segrelles C, Ruiz S, Santos M, Martinez-Palacio J, Lara MF, Paramio JM. Akt mediates an angiogenic switch in transformed keratinocytes. Carcinogenesis 2004;25:1137-47.
20. Amornphimoltham P, Sriuranpong V, Patel V, et al. Persistent activation of the Akt pathway in head and neck squamous cell carcinoma: a potential target for UCN-01. Clin Cancer Res 2004;10:4029-37.
21. Molinolo AA, Hewitt SM, Amornphimoltham P, et al. Dissecting the Akt/mammalian target of rapamycin signaling network: emerging results from the head and neck cancer tissue array initiative. Clin Cancer Res 2007;13:4964-73.
22. Segrelles C, Moral M, Lara MF, et al. Molecular determinants of Akt-induced keratinocyte transformation. Oncogene 2006;25:1174-85.
23. Pedrero JM, Carracedo DG, Pinto CM, et al. Frequent genetic and biochemical alterations of the PI 3-K/AKT/PTEN pathway in head and neck squamous cell carcinoma. Int J Cancer 2005;114:242-8.
24. Segrelles C, Ruiz S, Perez P, et al. Functional roles of Akt signaling in mouse skin tumorigenesis. Oncogene 2002;21:53-64.
25. Minamino T, Miyauchi H, Tateno K, Kunieda T, Komuro I. Akt-induced cellular senescence: implication for human disease. Cell Cycle 2004;3:449-51.
26. Chen Z, Trotman LC, Shaffer D, et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 2005;436:725-30.
27. Kim JS, Lee C, Bonifant CL, Ressom H, Waldman T. Activation of p53-dependent growth suppression in human cells by mutations in PTEN or PIK3CA. Mol Cell Biol 2007;27:662-77.
28. Saegusa M, Hashimura M, Kuwata T, Hamano M, Okayasu I. β-Catenin simultaneously induces activation of the p53-21WAF1 pathway and overexpression of cyclin D1 during squamous differentiation of endometrial carcinoma cells. Am J Pathol 2004;164:1739-49.
29. de Stanchina E, Querido E, Narita M, et al. PML is a direct p53 target that modulates p53 effector functions. Mol Cell 2004;13:523-35.
30. Salomoni P, Pandolfi PP. The role of PML in tumor suppression. Cell 2002;108:165-70.
31. Pearson M, Carbone R, Sebastiani C, et al. PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature 2000;406:207-10.
32. Miyauchi H, Minamino T, Tateno K, Kunieda T, Toko H, Komuro I. Akt negatively regulates the in vitro life span of human endothelial cells via a p53/p21-dependent pathway. EMBO J 2004;23:212-20.
33. Ruiz S, Santos M, Lara MF, Segrelles C, Ballestin C, Paramio JM. Unexpected roles for pRb in mouse skin carcinogenesis. Cancer Res 2005;65:9678-86.
34. Marino S, Krimpenfort P, Leung C, et al. PTEN is essential for cell migration but not for fate determination and tumourigenesis in the cerebellum. Development 2002;129:3513-22.
35. Allen CT, Ricker JL, Chen Z, Van Waes C. Role of activated nuclear factor-κB in the pathogenesis and therapy of squamous cell carcinoma of the head and neck. Head Neck 2007;29:959-71.
36. Leeman RJ, Lui VW, Grandis JR. STAT3 as a therapeutic target in head and neck cancer. Expert Opin Biol Ther 2006;6:231-41.
37. Sriuranpong V, Park JI, Amornphimoltham P, Patel V, Nelkin BD, Gutkind JS. Epidermal growth factor receptor-independent constitutive activation of STAT3 in head and neck squamous cell carcinoma is mediated by the autocrine/paracrine stimulation of the interleukin 6/gp130 cytokine system. Cancer Res 2003;63:2948-56.
38. Lu SL, Herrington H, Reh D, et al. Loss of transforming growth factor-h type II receptor promotes metastatic head-and-neck squamous cell carcinoma. Genes Dev 2006;20:1331-42.
39. Nakagawa H, Wang TC, Zukerberg L, et al. The targeting of the cyclin D1 oncogene by an Epstein-Barr virus promoter in transgenic mice causes dysplasia in the tongue, esophagus and forestomach. Oncogene 1997;14:1185-90.
40. Opitz OG, Harada H, Suliman Y, et al. Amouse model of human oral-esophageal cancer. J Clin Invest 2002;110:761-9.
41. Caulin C, Nguyen T, Longley MA, Zhou Z, Wang XJ, Roop DR. Inducible activation of oncogenic K-ras results in tumor formation in the oral cavity. Cancer Res 2004;64:5054-8.
42. Guasch G, Schober M, Pasolli HA, Conn EB, Polak L, Fuchs E. Loss of TGFh signaling destabilizes homeostasis and promotes squamous cell carcinomas in stratified epithelia. Cancer Cell 2007;12:313-27.
43. Bussink J, van der Kogel AJ, Kaanders JH. Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer. Lancet Oncol 2008;9:288-96.